Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Galectin-3 Level in Ankylosing Spondylitis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04746196
Recruitment Status : Completed
First Posted : February 9, 2021
Last Update Posted : April 20, 2021
Sponsor:
Information provided by (Responsible Party):
Gul Devrimsel, Recep Tayyip Erdogan University Training and Research Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Condition or disease Intervention/treatment
Ankylosing Spondylitis Other: Serum galectin-3 concentration was measured.

Detailed Description:

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs.

We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 80 participants
Observational Model: Other
Time Perspective: Other
Official Title: Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : June 30, 2017
Actual Study Completion Date : August 30, 2017

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
45 ankylosing spondylitis patients.
Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
 Other: Serum galectin-3 concentration was measured.
Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
35 controls
Healthy controls
 Other: Serum galectin-3 concentration was measured.
Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients [ Time Frame: 5 months ]
    Correlation


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Ankylosing spondylitis patients and healthy controls
Criteria

Inclusion Criteria:

  • Ankylosing spondylitis patients
  • Healthy controls

Exclusion Criteria:

  • Hyperlipidemia
  • Liver diseases
  • Renal diseases
  • Hematological diseases
  • Familial thyroid diseases
  • Neoplastic diseases
  • Autoimmune infectious diseases
  • Receiving anti-inflammatory drugs.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Gul Devrimsel, Clinical Professor, Recep Tayyip Erdogan University Training and Research Hospital
ClinicalTrials.gov Identifier: NCT04746196    
Other Study ID Numbers: 2016/85
First Posted: February 9, 2021    Key Record Dates
Last Update Posted: April 20, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infections
Bone Diseases
Musculoskeletal Diseases
 Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis